中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 5
May  2013
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2013  >  29(5): 385-388

Recent progress in understanding the role of microRNAs in hepatic stellate cell biology and liver fibrosis pathogenesis

Research funding:

 

  • Published Date: 2013-05-20
    Abstract

  • Small non-coding RNAs (2122nt in length;known as microRNAs, miRNAs) regulate a broad array of biological processes by disrupting gene expression through physically degrading or inhibiting translation of target mRNA sequences.miRNA-mediated regulation of gene expression has been demonstrated in both physiologic and pathogenic processes of cellular differentiation, proliferation, and death.Recent studies of liver fibrosis have begun to implicate miRNAs in the disease development and progression, which in turn suggests a potential new perspective for preventive and therapeutic molecular strategies.In this review, we summarize the various miRNAs identified as differentially expressed under conditions of liver fibrosis and then detail the latest findings regarding their roles in activation of hepatic stellate cells (HSCs) , the key early event in liver fibrosis.In addition, the latest findings regarding which signaling pathways and factors (such as cytokines, growth and apoptotic factors) these miRNAs interact with and modulate are discussed to provide a comprehensive insight into the fibrosis-related functions of miRNAs which may be manipulated to reduce, halt, or reverse the fibrotic process.

     

    • FullText(HTML)
    • References(36)
  • [1]Fan XQ, Chen XH, Qi XY.Research progress on targeted connectivetissue growth factor of siRNA for hepatic stellate cell mediated liver fi-brosis[J].Chin Med Herald, 2012, 9 (35) :58-60. (in Chinese) 樊雪强, 陈新华, 齐晓艳.靶向结缔组织生长因子的siRNA对于肝星状细胞介导肝纤维化的研究进展[J].中国医药导报, 2012, 9 (35) :58-60.
    [2]Cai FS.Clinical efficacy of Dahuang Zhechong pills combined with lami-vudine in treatment of hepatic fibrosis in chronic hepatis B[J].J Chang-chun Uni Tradit Chin Med, 2011, 27 (6) :1007-1008.蔡丰穗.大黄蟅虫丸联合拉米夫定治疗慢性乙型肝炎肝纤维化临床观察[J].长春中医药大学学报, 2011, 27 (6) :1007-1008.
    [3]Haybaeck J, Zeller N, Heikenwalder M.The parallel universe:microR-NAs and their role in chronic hepatitis, liver tissue damage and hepato-carcinogenesis[J].Swiss Med Wkly, 2011, 141:w13287.
    [4]Noetel A, Kwiecinski M, Elfimova N, et al.microRNA are centralplayers in anti-and profibrotic gene regulation during liver fibrosis[J].Front Physiol, 2012, 3:49.
    [5]Guo CJ, Pan Q, Cheng T, et al.Changes in microRNAs associatedwith hepatic stellate cell activation status identify signaling pathways[J].FEBS J, 2009, 276 (18) :5163-5176.
    [6]Murakami Y, Toyoda H, Tanaka M, et al.The progression of liverfibrosis is related with overexpression of the miR-199 and 200 fam-ilies[J].PLoS One, 2011, 6 (1) :e16081.
    [7]Chen C, Wu CQ, Zhang ZQ, et al.Loss of expression of miR-335is implicated in hepatic stellate cell migration and activation[J].Experimental Cell Research, 2011, 317 (12) :1714-1725.
    [8]Lakner AM, Steuerwald NM, Walling TL, et al.Inhibitory effectsof microRNA 19b in hepatic stellate cell-mediated fibrogenesis[J].Hepatology, 2012, 56 (1) :300-310.
    [9]Wang B, Li W, Guo K, et al.miR-181b Promotes hepatic stellatecells proliferation by targeting p27 and is elevated in the serum ofcirrhosis patients[J].Biochem Biophys Res Commun, 2012, 421 (1) :4-8.
    [10]Sekiya Y, Ogawa T, Yoshizato K, et al.Suppression of hepaticstellate cell activation by microRNA-29b[J].Biochem BiophysRes Commun, 2011, 412 (1) :74-79.
    [11]Kwiecinski M, Elfimova N, Noetel AT, et al.Expression of platelet-derived growth factor-C and insulin-like growth factor I in he-patic stellate cells is inhibited by miR-29[J].Lab Invest, 2012, 92 (7) :978-987.
    [12]Kwiecinski M, Noetel A, Elfimova N, et al.Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells bymiRNA-29 induction[J].PLoS One, 2011, 6 (9) :e24568.
    [13]Venugopal SK, Jiang J, Kim TH, et al.Liver fibrosis causes down-regulation of miRNA-150 and miRNA-194 in hepatic stellatecells, and their overexpression causes decreased stellate cell activa-tion[J].Am J Physiol Gastrointest Liver Physiol, 2010, 298 (1) :G101-106.
    [14]Guo CJ, Pan Q, Li DG, et al.miR-15b and miR-16 are impli-cated in activation of the rat hepatic stellate cell:An essential rolefor apoptosis[J].J Hepatol, 2009, 50 (4) :766-778.
    [15]Guo CJ, Pan Q, Jiang B, et al.Effects of upregulated expression ofmicroRNA-16 on biological properties of culture-activated hepat-ic stellate cells[J].Apoptosis, 2009, 14 (11) :1331-1340.
    [16]Li WQ, Chen C, Xu MD, et al.The rno-miR-34 family is up-regulated and targets ACSL1 in dimethylnitrosamine-induced he-patic fibrosis in rats[J].FEBS J, 2011, 278 (9) :1522-1532.
    [17]Ogawa T, Enomoto M, Fujii H, et al.MicroRNA-221/222 upreg-ulation indicates the activation of stellate cells and the progression ofliver fibrosis[J].Gut, 2012, 61 (11) :1600-1609.
    [18]He Y, Huang C, Sun X, et al.MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targetingSMAD4[J].Cell Signal, 2012, 24 (10) :1923-1930.
    [19]Huebert RC, Jagavelu K, Hendrickson HI, et al.Aquaporin-1promotes angiogenesis, fibrosis, and portal hypertension throughmechanisms dependent on osmotically sensitive microRNAs[J].Am J Pathol, 2011, 179 (4) :1851-1860.
    [20]Jiang A, Zhang S, Li Z, et al.miR-615-3p promotes the phago-cytic capacity of splenic macrophages by targeting ligand-depend-ent nuclear receptor corepressor in cirrhosis-related portal hyper-tension[J].Exp Biol Med (Maywood) , 2011, 236 (6) :672-680.
    [21]Gui J, Tian Y, Wen X, et al.Serum microRNA characterizationidentifiesmiR-885-5pas a potential marker for detecting liver pa-thologies[J].Clinical Science, 2011, 120 (5) :183-193.
    [22]Yoshida K, Matsuzaki K.Differential regulation of TGF-beta/Smad signaling in hepatic stellate cells between acute and chronicliver injuries[J].Front Physiol, 2012, 3:53.
    [23]Fang Y, Yu S, Braley-Mullen H.TGF-beta promotes prolifera-tion of thyroid epithelial cells in IFN-gamma (-/-) mice bydown-regulation of p21 and p27 via AKT pathway[J].Am JPathol, 2012, 180 (2) :650-660.
    [24]El-Karef A, Yoshida T, Gabazza EC, et al.Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis inmice[J].J Pathol, 2007, 211 (1) :86-94.
    [25]Bonner JC.Regulation of PDGF and its receptors in fibrotic diseases[J].Cytokine Growth Factor Rev, 2004, 15 (4) :255-273.
    [26]Sobrevals L, Rodriguez C, Romero-Trevejo JL, et al.Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysisand reduces fibrogenesis leading to cirrhosis reversion in rats[J].Hepatology, 2010, 51 (3) :912-921.
    [27]Wu YL, Wan Y, Jin XJ, et al.25-OCH3-PPD induces the ap-optosis of activated t-HSC/Cl-6 cells via c-FLIP-mediated NF-kappaB activation[J].Chem Biol Interact, 2011, 194 (2-3) :106-112.
    [28]Novo E, Marra F, Zamara E, et al.Overexpression of Bcl-2 byactivated human hepatic stellate cells:resistance to apoptosis as amechanism of progressive hepatic fibrogenesis in humans[J].Gut, 2006, 55 (8) :1174-1182.
    [29]Leist M, Jaattela M.Four deaths and a funeral:from caspases to alter-native mechanisms[J].Nat Rev Mol Cell Biol, 2001, 2 (8) :589-598.
    [30]Ramani K, Tomasi ML.Transcriptional regulation of methionine ad-enosyltransferase 2A by peroxisome proliferator-activated receptorsin rat hepatic stellate cells[J].Hepatology, 2012, 55 (6) :1942-1953.
    [31] Galli A, Crabb D, Price D, et al.Peroxisome proliferator-activa-ted receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepaticstellate cells[J].Hepatology, 2000, 31 (1) :101-108.
    [32]Ji J, Zhang J, Huang G, et al.Over-expressed microRNA-27aand 27b influence fat accumulation and cell proliferation during rathepatic stellate cell activation[J].FEBS Lett, 2009, 583 (4) :759-766.
    [33]Kida K, Nakajima M, Mohri T, et al.PPARalpha is regulated bymiR-21 and miR-27b in human liver[J].Pharm Res 2011, 28 (10) :2467-2476.
    [34]Yang MD, Chiang YM, Higashiyama R, et al.Rosmarinic acid and ba-icalin epigenetically derepress peroxisomal proliferator-activated recep-tor gamma in hepatic stellate cells for their antifibrotic effect[J].Hepa-tology, 2012, 55 (4) :1271-1281.
    [35]Mann J, Chu DC, Maxwell A, et al.MeCP2 controls an epigeneticpathway that promotes myofibroblast transdifferentiation and fibrosis[J].Gastroenterology, 2010, 138 (2) :705-714, 714.e701-704.
    [36]Hu XL, Fan GR.Functional role of microRNAs in viral hepatitis in-fections[J].J Clin Hepatol, 2012, 28 (11) :877-880. (in Chi-nese) 胡学玲, 范公忍, microRNA在乙型, 丙型肝炎中的作用[J].临床肝胆病杂志, 2012, 28 (11) :877-880.
    • Relative Articles

  • Relative Articles

    [1]Yuanpeng MAO, Zhe YU, Aqian SONG, Hongshan WEI. From viral hepatitis to hepatocellular carcinoma: The role of exosomal microRNAs[J]. Journal of Clinical Hepatology, 2023, 39(2): 439-443. doi: 10.3969/j.issn.1001-5256.2023.02.030
    [2]Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
    [3]Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
    [4]Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
    [5]Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
    [6]Wu Jie, Li JingTao, Wei HaiLiang, Yan ShuGuang, Fan Yu, Guo YingJun, Chang ZhanJie. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. Journal of Clinical Hepatology, 2020, 36(7): 1650-1654. doi: 10.3969/j.issn.1001-5256.2020.07.045
    [7]Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
    [8]Xu Ying, Zhang DingQi, Chen JiaMei, Liu Wei, Liu Ping. Effect of various cells on the activation of hepatic stellate cells in liver microenvironment[J]. Journal of Clinical Hepatology, 2019, 35(2): 424-430. doi: 10.3969/j.issn.1001-5256.2019.02.042
    [9]Huang XiangJun, Zhang WenXing. Expression features and clinical significance of the microRNA-888 gene family in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 119-122. doi: 10.3969/j.issn.1001-5256.2019.01.022
    [10]Niu YaQian, Chang YuLing, Liu Fang, Zhao Chuan, Chen Che. Regulatory role of microRNA in aerobic glycolysis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(9): 2082-2084. doi: 10.3969/j.issn.1001-5256.2019.09.044
    [11]Geng YaJun, Li ShuDong, Liu ShenZheng, Ren JianJun, Zhang Tong. Inhibitory effect of microRNA-149-5p in the proliferation and migration of HepG2 and Bel-7402 hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(6): 1126-1130. doi: 10.3969/j.issn.1001-5256.2017.06.022
    [12]Zhang YuRui. Correlation between microRNA-520a and clinicopathological features of HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(4): 689-693. doi: 10.3969/j.issn.1001-5256.2017.04.018
    [13]Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
    [14]Qiu Hua, Sun XueHua, Zhou ZhenHua, Li Man, Zhang Xin, Gao YueQiu. Influence of interaction between endogenous miRNAs and hepatitis B virus in hepatocytes on hepatitis B virus transcription and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(11): 2186-2190. doi: 10.3969/j.issn.1001-5256.2016.11.042
    [15]Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
    [16]Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
    [17]Xiao ZuoHan, Meng Gang, Wang LiZhi, Sun WenJin. Diagnostic value of combined determination of DNA ploidy level and miRNA-21 expression in ascites cells for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 93-98. doi: 10.3969/j.issn.1001-5256.2015.01.020
    [18]Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
    [19]Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
    [20]Guo JinSheng. Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy [J]. Journal of Clinical Hepatology, 2013, 29(5): 324-326.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 5.2 %FULLTEXT: 5.2 %META: 91.3 %META: 91.3 %PDF: 3.5 %PDF: 3.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.0 %其他: 5.0 %China: 1.7 %China: 1.7 %Pakistan: 0.2 %Pakistan: 0.2 %上海: 5.2 %上海: 5.2 %保定: 0.5 %保定: 0.5 %北京: 6.5 %北京: 6.5 %南京: 1.0 %南京: 1.0 %南宁: 0.2 %南宁: 0.2 %台州: 0.2 %台州: 0.2 %吉林: 0.5 %吉林: 0.5 %哥伦布: 0.2 %哥伦布: 0.2 %张家口: 3.5 %张家口: 3.5 %成都: 0.5 %成都: 0.5 %昆明: 0.7 %昆明: 0.7 %杭州: 0.7 %杭州: 0.7 %洛阳: 0.2 %洛阳: 0.2 %深圳: 0.7 %深圳: 0.7 %石家庄: 0.5 %石家庄: 0.5 %芒廷维尤: 35.7 %芒廷维尤: 35.7 %芝加哥: 0.2 %芝加哥: 0.2 %莫斯科: 1.5 %莫斯科: 1.5 %衡水: 0.2 %衡水: 0.2 %西宁: 32.5 %西宁: 32.5 %重庆: 0.2 %重庆: 0.2 %长春: 0.2 %长春: 0.2 %长沙: 0.7 %长沙: 0.7 %青岛: 0.2 %青岛: 0.2 %其他ChinaPakistan上海保定北京南京南宁台州吉林哥伦布张家口成都昆明杭州洛阳深圳石家庄芒廷维尤芝加哥莫斯科衡水西宁重庆长春长沙青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (3353) PDF downloads(785) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2509]YesterdayPV[4800]TodayIP[141]TodayPV[193]Online[38]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return